
Developing and commercializing transformative medicines for life-limiting nervous system diseases.
Engrail Therapeutics is a clinical-stage pharmaceutical company focused on developing and commercializing transformative medicines for life-limiting nervous system diseases. The company leverages its scientific expertise in molecular mechanisms and neurocircuitry to address the needs of patients with devastating neurological disorders. Engrail's core mission is to transform the lives of these patients through precision neuroscience, offering innovative therapies that target complex conditions.
Notable affiliated individuals and investors include experienced professionals in the pharmaceutical and biotech industries, though specific names are not provided. Key achievements include advancing their pipeline of treatments to clinical stages, demonstrating their commitment to impactful medical innovation. Engrail Therapeutics aims to make a significant impact on the healthcare market by providing effective solutions for previously unmet medical needs in neurology.

Pipeline Therapeutics

Escape Bio
escapebio.com

NeuroTherapeutics Pharma

Chase Therapeutics

Novoron Bioscience
novoron.com

Eikon Therapeutics
eikontx.com

Enterin
enterininc.com

Spinogenix
spinogenix.com

Cerebral Therapeutics

Neuron23

Neurovia

Nido Biosciences
nidobio.com

NeuroGenetic Pharmaceuticals

Cygnal Therapeutics

Axonis Therapeutics
Companies similar to Engrail Therapeutics include Pipeline Therapeutics, Escape Bio, NeuroTherapeutics Pharma and Chase Therapeutics.
Engrail Therapeutics was founded in 2019.
Engrail Therapeutics' headquarters is located in San Diego, CA, US.
Engrail Therapeutics' most recent funding round was for $32M (USD) in August 2021.
As of Aug 3, 2021, Engrail Therapeutics has raised a total of $64M (USD).
Engrail Therapeutics has 23 employees as of Feb 4, 2024.